These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28633317)

  • 21. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Precision" drug development?
    Woodcock J
    Clin Pharmacol Ther; 2016 Feb; 99(2):152-4. PubMed ID: 26331240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How will the FDA impact the laboratory developed test?
    Davis J; Wentz J
    Clin Lab Sci; 2007; 20(3):130-1. PubMed ID: 17691668
    [No Abstract]   [Full Text] [Related]  

  • 24. A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response-Guided Titration.
    Wang L; Maxfield K; Guinn D; Madabushi R; Zineh I; Schuck RN
    Clin Pharmacol Ther; 2021 Jan; 109(1):123-130. PubMed ID: 33022770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
    Shakhnovich V; Meibohm B; Rosenberg A; Kierzek AM; Hasenkamp R; Funk RS; Thalhauser CJ; van der Graaf PH; Wang YC; Hamuro L
    Clin Transl Sci; 2020 Mar; 13(2):219-223. PubMed ID: 31762152
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer.
    Sarvas H; Carlisle B; Dolter S; Vinarov E; Kimmelman J
    J Natl Cancer Inst; 2020 Aug; 112(8):859-862. PubMed ID: 31722417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On the readiness of physicians for pharmacogenomics testing: an empirical assessment.
    Amara N; Blouin-Bougie J; Bouthillier D; Simard J
    Pharmacogenomics J; 2018 Apr; 18(2):308-318. PubMed ID: 28607504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implementation of genetic testing in medicine: a US regulatory science perspective.
    Lesko LJ; Schmidt S
    Br J Clin Pharmacol; 2014 Apr; 77(4):606-11. PubMed ID: 24286486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 30. US personalized-medicine industry takes hit from Supreme Court.
    Ledford H
    Nature; 2016 Aug; 536(7617):382. PubMed ID: 27558042
    [No Abstract]   [Full Text] [Related]  

  • 31. The path to personalized medicine.
    Hamburg MA; Collins FS
    N Engl J Med; 2010 Jul; 363(4):301-4. PubMed ID: 20551152
    [No Abstract]   [Full Text] [Related]  

  • 32. The FDA and me.
    Nature; 2013 Dec; 504(7478):7-8. PubMed ID: 24312954
    [No Abstract]   [Full Text] [Related]  

  • 33. Advances in clinical genomics.
    Lowe AM
    Virtual Mentor; 2012 Aug; 14(8):635-9. PubMed ID: 23351319
    [No Abstract]   [Full Text] [Related]  

  • 34. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
    Loomba R; Ratziu V; Harrison SA;
    Gastroenterology; 2022 Mar; 162(3):680-688. PubMed ID: 34822801
    [No Abstract]   [Full Text] [Related]  

  • 35. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
    Meyer RJ
    Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Railroading at the FDA.
    Nat Med; 2016 Nov; 22(11):1193. PubMed ID: 27824816
    [No Abstract]   [Full Text] [Related]  

  • 37. Incurred sample reproducibility in pharmacokinetic bioanalysis: pros and cons from a CRO perspective.
    Timmons BM; Hay L; Gorman J; Stouffer B
    Bioanalysis; 2018 Nov; 10(21):1715-1717. PubMed ID: 30412674
    [No Abstract]   [Full Text] [Related]  

  • 38. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
    Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
    J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marketing of personalized cancer care on the web: an analysis of Internet websites.
    Gray SW; Cronin A; Bair E; Lindeman N; Viswanath V; Janeway KA
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25745021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new era of genetic testing and its impact on research and clinical care.
    Baudhuin LM
    Clin Chem; 2012 Jun; 58(6):1070-1. PubMed ID: 22811991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.